| 6 | 1/1 | 返回列表 |
| 查看: 1464 | 回復: 5 | |||
[交流]
輝瑞公司停止開發(fā)丙型肝炎藥物 已有5人參與
|
|
輝瑞制藥有限公司(Pfizer Inc., PFE, 簡稱:輝瑞公司)已停止丙型肝炎藥物的試驗開發(fā),退出了行業(yè)內為引入新一代丙型肝炎治療藥而進行的激烈競爭。 該公司發(fā)言人Victoria Davis稱,公司在進行戰(zhàn)略評估后決定停止Filibuvir的開發(fā)。她表示,這一決定與安全問題無關。 該藥在停止開發(fā)前處于中期臨床試驗階段 |

至尊木蟲 (小有名氣)
|
Combination of filibuvir and peginterferon alfa-2a/ribavirin evaluated in HCV patients -------------------------------------------------------------------------------- Filibuvir (PF-00868554; Pfizer) has previously been evaluated as monotherapy in patients with hepatitis C (HCV), and whether the activity seen in that study could be enhanced by combination with peginterferon alfa-2a and ribavirin has now been assessed in a randomized, placebo-controlled trial. Patients with genotype 1 HCV (N = 35) were treated with filibuvir 200, 300 or 500 mg b.i.d. or placebo plus peginterferon alfa-2a 180 mcg/week and ribavirin 1000/1200 mg/day for 4 weeks, with the peginterferon/ribavirin treatment continuing for a further 44 weeks. During the 4-week filibuvir treatment period, the combination therapy was well tolerated, with headache, fatigue, insomnia and nausea the most common adverse events. Adverse events did not appear to be related to filibuvir dose. One serious adverse event related to treatment, elevated creatinine, was seen in the filibuvir 300 mg group. Mean reductions in HCV RNA at day 28 were -2.10, -4.46, -4.67 and -3.62 log10 IU/mL for the placebo and filibuvir 200, 300 and 500 mg groups, respectively. In these groups, 0, 60, 75 and 63% of patients achieved undetectable HCV RNA by week 4 (Jacobson, I. et al. 44th Annu Meet Eur Assoc Study Liver (EASL) (April 22-26, Copenhagen) 2009, Abst). |

木蟲 (著名寫手)
muchong

榮譽版主 (知名作家)
金蟲 (正式寫手)
| 6 | 1/1 | 返回列表 |
| 最具人氣熱帖推薦 [查看全部] | 作者 | 回/看 | 最后發(fā)表 | |
|---|---|---|---|---|
|
[考研] 求調劑 +3 | 暗涌afhb 2026-03-16 | 3/150 |
|
|---|---|---|---|---|
|
[考研] 一志愿西安交通大學材料工程專業(yè) 282分求調劑 +5 | 楓橋ZL 2026-03-18 | 7/350 |
|
|
[考研] 286求調劑 +6 | lemonzzn 2026-03-16 | 10/500 |
|
|
[考研] 求調劑,一志愿:南京航空航天大學大學 ,080500材料科學與工程學碩,總分289分 +3 | @taotao 2026-03-19 | 3/150 |
|
|
[考研] 一志愿中海洋材料工程專碩330分求調劑 +7 | 小材化本科 2026-03-18 | 7/350 |
|
|
[考研] 材料080500調劑求收留 +4 | 一顆meteor 2026-03-13 | 4/200 |
|
|
[考研] 085410人工智能專碩317求調劑(0854都可以) +3 | xbxudjdn 2026-03-18 | 3/150 |
|
|
[考研] 295求調劑 +3 | 一志愿京區(qū)211 2026-03-18 | 5/250 |
|
|
[考研] 297求調劑 +8 | 戲精丹丹丹 2026-03-17 | 8/400 |
|
|
[考研] 304求調劑 +12 | 小熊joy 2026-03-14 | 13/650 |
|
|
[考研] 生物學071000 329分求調劑 +3 | 我愛生物生物愛?/a> 2026-03-17 | 3/150 |
|
|
[考研] 考研求調劑 +3 | 橘頌. 2026-03-17 | 4/200 |
|
|
[考研] 085601求調劑 +4 | Du.11 2026-03-16 | 4/200 |
|
|
[考研] 考研調劑 +3 | 淇ya_~ 2026-03-17 | 5/250 |
|
|
[考研] 一志愿,福州大學材料專碩339分求調劑 +3 | 木子momo青爭 2026-03-15 | 3/150 |
|
|
[考研] 321求調劑 +5 | 大米飯! 2026-03-15 | 5/250 |
|
|
[考研] 中科大材料專碩319求調劑 +3 | 孟鑫材料 2026-03-13 | 3/150 |
|
|
[考研] 297一志愿上交085600求調劑 +5 | 指尖八千里 2026-03-14 | 5/250 |
|
|
[考研] 311求調劑 +3 | 冬十三 2026-03-13 | 3/150 |
|
|
[碩博家園] 085600 260分求調劑 +3 | 天空還下雨么 2026-03-13 | 5/250 |
|